Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251743 · ClinicalTrials.gov registry record · NA
Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD
A NA study, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 144
- Enrollment target
NCT02251743 is a NA study that has completed, run by Ohio State University. The registered enrollment target is 144 participants.
The verdict
NCT02251743, a NA study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
Study Summary
Additional treatments with long-term benefit for attention-deficit/hyperactivity disorder (ADHD) are needed; one of the more promising is neurofeedback (EEG biofeedback), which has several randomized controlled trials showing significant benefit, but which are inconclusive because they were not double-blinded; the benefit could have been nonspecific (placebo response). Because of neurofeedback's labor-intensive cost (1 treatment costing as much as a month's medication), It is important to know how much specific benefit it yields. This 2- site placebo-controlled double-blind randomized clinical trial is the first to test for a specific benefit of neurofeedback with adequate power, the first designed and implemented collaboratively by experts in neurofeedback, ADHD, and clinical trials, the first to rigorously monitor quality not only of treatment, but also of placebo and blinding, and the first to follow up for 2 years to examine enduring effect; the results, whether positive or negative, will provide evidence for clinical practice and public policy regarding ADHD.
Interventions
- DEVICE Neurofeedback treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2014-09 |
| Est. Completion | 2020-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02251743
The ClinicalTrials.gov registry entry for NCT02251743 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neurofeedback treatment is the first listed.
NCT02251743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02251743 about?
NCT02251743 is a clinical study titled "Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD". Additional treatments with long-term benefit for attention-deficit/hyperactivity disorder (ADHD) are needed; one of the more promising is neurofeedback (EEG biofeedback), which has several randomized controlled trials showing significant benefit, but which are inconclusive because they were not doub...
What is the current status of trial NCT02251743?
This trial is currently completed. It is a NA study. The enrollment target is 144 participants. The study started on 2014-09. Estimated completion is 2020-08.
What interventions are being tested in trial NCT02251743?
The interventions under investigation include: Neurofeedback treatment (DEVICE).
Who is sponsoring clinical trial NCT02251743?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.